Background: Difficulty modeling complex behavioral phenotypes in rodents (e.g., language) has hindered pathophysiological investigation and treatment development for autism spectrum disorders. Recent human neuroimaging studies, however, have identified functional biomarkers that can be more directly related to the abnormal neural dynamics of autism spectrum disorders. This study assessed the translational potential of auditory evoked-response endophenotypes of autism in parallel mouse and human studies of autism.
A utism spectrum disorders (ASD) are highly heritable neurodevelopmental disorders characterized by reduced social interactions, language impairment, and repetitive or restricted interests and behaviors. Despite strong genetic etiology, diagnosis is based purely on behavioral criteria. However, individuals with ASD display marked phenotypic heterogeneity and frequent medical comorbidities, which have hindered advances in diagnosis and treatment development (1) . It is likely that underlying structural or functional neural abnormalities associated with ASD might be more robust targets for diagnostic and therapeutic advancement than behavioral phenotypes (2) .
With magnetoencephalography (MEG), we recently proposed a neural biomarker for autism (3) . Specifically, autistic children showed delays in the superior temporal gyrus (STG) 100-msec auditory response (M100), with this latency prolongation providing accurate ASD classification. The present study builds on these findings by investigating ␥ frequency synchronization in this same group of subjects. Emerging evidence suggests that neural synchrony is disturbed in autism, particularly in the ␥-band (30 -50 Hz) (4) . Such oscillations are important for sensory integration and connectivity, which are disturbed in autism, and might relate to deficits in cortical inhibition (5-7). We examine power and phase-locking, the similarity in phase across trials, in ASD and typically developing control subjects as well as the association between frequency measures and M100 latency.
Difficulty modeling complex human behaviors, like language, in rodents has been a significant obstacle for translational studies of autism. Here, the utility of electrophysiological biomarkers in preclinical investigation was examined. With an analogous auditory paradigm, latency delays and ␥-band responses were investigated in the valproic acid (VPA) mouse model of autism. Prenatal VPA exposure in humans is associated with a 7-10ϫ increase in relative risk for ASD (8 -11) . In rats, prenatal VPA exposure is an emerging insult-based model of autism with a well-replicated phenotype including reduced social preference, increased repetitive behaviors, and deficits in sensorimotor integration (12) (13) (14) . The VPA-exposed rodents demonstrate cerebellar and brainstem pathologies, downregulation of autism risk genes, and altered excitatory/inhibitory balance, all abnormalities consistent with theories of ASD pathophysiology (15) (16) (17) (18) (19) (20) . Despite these results, few studies have explored prenatal VPA exposure in mice. Replicating human behavioral and electrophysiological deficits in mice would bolster the validity of this model and offer new targets for preclinical therapeutic development.
The goals of this study were severalfold. First, we characterized two functional ASD biomarkers. Next, we performed an extensive behavioral battery in the VPA mouse model and assessed analogues of the human electrophysiological endophenotypes. Finally, we attempted to rescue neural deficits in the mice with the metabotropic glutamate receptor (mGluR)5 receptor antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP), which ameliorates aberrant phenotypes in other mouse models relevant to autism (21) .
Methods and Materials

Subjects
The STG M100 latency findings for these subjects were previously reported (3) . In this study, data were further analyzed to examine left-and right-hemisphere STG ␥ power and phase-locking. The MEG data collection and analysis procedures are briefly described in the following. Children with ASD (n ϭ 25, age 10.20 Ϯ
Animals
The C57BL/6Hsd (B6) mice were obtained at 7-8 weeks of age from Harlan (Indianapolis, Indiana) and were mated, with pregnancy confirmed by the presence of a vaginal plug on embryonic day 0 (E0). On E13, pregnant females (n ϭ 18) received a single subcutaneous injection of 600 mg/kg VPA (Tocris BioScience, Ellisville, Missouri) dissolved in saline (SAL). Control females (n ϭ 13) received an equal volume of SAL only. There were 39 pups delivered from VPA-treated dams, and 43 pups from SAL-treated females. Day of birth was recorded as P0. Animals were maintained in a standard 12-hour light/dark cycle with free access to food and water. Protocols were approved by the University of Pennsylvania Institutional Animal Care and Use Committee.
Behavior
From P0 to P70, mice underwent a battery of behavioral tests conducted in the following order: neonatal vocalizations (P2-P12), developmental milestones (P2-P20), prepulse inhibition (PPI) of startle (P35), locomotor testing (P42), open field testing (P49), social testing (P56), rotarod (P63), adult vocalizations (70), and olfactory testing (P75) (Supplement 1).
Electrophysiology
At 12 weeks, animals underwent stereotaxic implantation of a stainless steel tripolar electrode assembly (Plastics1, Roanoke, Virginia) as published (24) . Animals were anesthetized with isoflurane, and a low-impedance (Ͻ 5 k⍀, 1000 Hz) macro-electrode was stereotaxically positioned between auditory cortex and auditory thalamus (1.4 mm posterior, 2.65 mm lateral, 2.75 mm deep relative to bregma) and referenced to frontal sinus. This configuration captures both early and late components of the auditory evoked potential (AEP), including the acoustic brainstem response, midlatency P20 (e.g., human P50/M50), and N40 (e.g., human N100/ M100) as published ( Figure 1 ) (25) (26) (27) .
One week after surgery, AEPs were recorded with Micro1401 hardware and Spike6 software (CED, Cambridge, United Kingdom). A total of 3000 6-and 9-kHz pure tones were presented with a 500-msec interstimulus interval at 85 dB. Time series and frequency analyses were performed in EEGLab with analogous methods as in the clinical study (Methods and Materials in Supplement 1). 
Western Blotting
Western blotting was performed as published, with anti-NLGN3 (rabbit polyclonal, sc-50395, Santa Cruz, 1:200) (Santa Cruz, California) and anti-␤-actin (mouse monoclonal, Abcam ab6276, 1:5000) (28) (Methods and Materials in Supplement 1).
Pharmacological Effects
The effect of the mGluR5 antagonist MPEP (Sigma, St. Louis, Missouri) was assessed on AEP and PPI phenotypes. Mice were injected with MPEP (10 mg/kg IP) dissolved in SAL 5 min before electrophysiological and behavioral testing. This dose was based on previous work demonstrating efficacy in mice (21) .
Statistics
Significance for all measures was assessed by repeated measures or one-way analysis of variance, followed by Fisher least significant difference (LSD) post hoc where appropriate. All exploratory comparisons were Bonferroni corrected for Type I error.
Results
Human MEG
As reported, subjects with ASD showed an approximate 10% delay in the right hemisphere M100 response ( Figure 2) [F (1,38) ϭ 7.6, p Ͻ .009] (3). With a cutoff of 116 msec, M100 latency classified ASD subjects with a sensitivity of 75% and specificity of 81% (3). Building on these findings, transient ␥-band power and phaselocking were calculated to assess neural oscillatory activity. The ASD subjects showed significantly reduced ␥ phase-locking across hemispheres ( Figure 2 
Significant zero-order correlations between M100 latency and ␥ PLF (R 2 ϭ .15, p ϭ .02, corrected; Figure 3A , left) suggest the measures are related but not redundant. Across groups, the peak M100 response occurred at 132 Ϯ 3.15 msec (mean Ϯ SEM), although the peak ␥-band response was at 95.1 Ϯ 7.4 msec. These latency distributions were highly distinct [F (1,83) ϭ 19.6, p ϭ .00003], indicating a significant separation between M100 and preceding ␥-band responses. Grand average time-frequency plots are shown in Figure S2 in Supplement 1.
Mouse Behavior
See Supplement There were no group differences in locomotor activity, rotorod motor coordination, olfactory function, or auditory startle curves, arguing against global neurological impairment.
Mouse Electrophysiology
For time-domain analyses ( Figure 2 ), amplitudes and latencies of P1 and N1 (e.g., N100/M100) were measured. The VPA-exposed mice showed a significant 16% delay in N1 latency to 6 kHz tones 
Mouse Molecular Biology
Expression of the autism risk gene neuroligin-3 (NLGN3)-an X-linked synaptic cell-adhesion molecule-was measured, given previous studies demonstrating that prenatal VPA exposure leads to reduced NLGN3 messenger RNA levels (21) . Group differences in NLGN3 optical density were not observed [F (1,11) ϭ 3.17, p ϭ .10]. The ␤-actin expression was identical between groups. It is possible that our study is underpowered to detect a group difference or that analyses in brain subregions would yield significant differences.
Regression analyses then assessed associations among electrophysiological measures, NLGN3 expression, and adult behaviors related to auditory processing and communicative function. The NLGN3 protein levels strongly predicted ␥ phase-locking across both SAL and VPA groups (R 2 ϭ .46, p Ͻ .04, corrected). In addition, ␥ PLF significantly predicted average PPI responses (R 2 ϭ .39, p Ͻ .01, corrected). There was no relationship between NLGN3 and N1 latency. There was a nonsignificant but qualitative relationship between N1 latency and premating vocalizations (R 2 ϭ .34, p ϭ .10, corrected), suggesting a potential link between receptive auditory processing and expressive communicative functioning in mice.
Pharmacological Effects
The predictive utility of electrophysiological biomarkers as targets for therapeutic development was explored. The effect of the mGluR5 antagonist MPEP was assessed on AEP and PPI measures. Across both groups, MPEP significantly reduced cortical excitability as measured by the N1 amplitude [F (1,14) ϭ 9.23, p Ͻ .009]. However, there was no effect of drug on N1 latency [F (1,14) ϭ 1.64, p ϭ .22]. In the frequency domain, there was a trend toward a significant group ϫ drug interaction [F (1,15) ϭ 3.77, p ϭ .07], in which MPEP reduced ␥ phase-locking in the SAL group while increasing ␥ PLF in the VPA group. This suggests that restoring the balance of excitation to inhibition in the VPA group might promote ␥ synchrony, whereas altering this balance in wild-type mice might disrupt ␥ synchrony.
The effect of MPEP was also assessed on PPI and startle phenotypes. There was no drug effect on startle amplitude [drug effect: F (1,22) 
Discussion
This study characterizes two electrophysiological endophenotypes of autism in parallel human and mouse studies. Autistic subjects show delayed M100 STG responses and reduced ␥-band phase-locking. In mice, prenatal VPA exposure causes selective behavioral alterations in domains affected in autism, including social and communicative functioning. The VPA model mirrors evokedresponse latency delays and ␥-band deficits identified in the clinical population. In mice, electrophysiological measures predict the severity of behavioral deficits and correlate with expression of the autism risk gene, NLGN3. Finally, the mGluR5 antagonist MPEP reverses PPI deficits and might modulate ␥-band dysfunction, suggesting that mGluR5 receptors might be appropriate therapeutic targets in autism.
Electrophysiological Biomarkers of Autism
Several studies suggest that early auditory encoding processes are impaired in ASD (29) . Here, autistic subjects showed delays in the STG M100 response, in accordance with previous reports of delayed M100/N100 latencies in ASD to simple and complex auditory stimuli (30 -32) . Delayed auditory evoked-responses have been demonstrated in unaffected relatives of autistic subjects, suggesting that such deficits might be heritable (33) . Taken together, these findings suggest that delayed AEPs are a replicable endophenotype of ASD. Although an underlying neural mechanism for this latency delay is unknown, recent studies have demonstrated a link between white-matter integrity and electrophysiological response timing (34, 35) . Given reports of widespread white-matter alterations in ASD, we speculate that latency delays might be related to poorly myelinated acoustic radiations and associated auditory processing pathways (36) . The contribution of such a neural deficit to core symptoms of ASD, if any, is also unclear. However, recent work suggests that deficits in the integrity of auditory processing are detrimental to speech and language acquisition, a core ASD impairment (37) .
Emerging evidence suggests that neural synchrony might be impaired in autism, particularly in the ␥-band, which might contribute to clinical deficits (4). The ␥ oscillations have been widely studied in regard to cognitive correlates, including attention and perceptual "feature binding," as well as neural mechanisms involving the tightly coupled interaction between pyramidal neurons and fast-spiking interneurons (5, 6, 38) . Previous studies have reported ␥-band abnormalities in ASD, during visual and auditory tasks (39) (40) (41) (42) (43) . However, other groups have failed to detect ␥-band deficits in ASD, suggesting that there might be relevant variables in diagnostic specificity or other aspects of study design that contribute to these divergent results (44) . Here, we demonstrate reduced ␥ phase-locking in autism. The PLF is a measure of local neural synchronization (phase coherence) across trials. As such, it is independent of oscillatory amplitude and therefore is a direct measure of synchronization. We found no group differences in induced ␥ power. Surprisingly, differences in evoked ␥ power, which tends to 1103 www.sobp.org/journal reflect phase-locking, were nonsignificant (p ϭ .1). However, these results are qualitatively very similar to our preclinical findings and those from other clinical studies, which have identified more significant group differences in ␥ phase-locking than evoked power (42, 45) . This difference could reflect increased noise in the extracranial MEG recordings relative to intracranial electrodes in mice. Our findings indicate that local auditory cortical networks do not synchronize appropriately to external stimuli in autism, which might contribute to or reflect deficits in auditory perception or attention. In accordance with our results, Rojas et al. (42) demonstrated reduced auditory ␥ PLF in adults with ASD, and Wilson et al. (43) reported reduced auditory steady-state ␥ responses in autism. The former study also showed ␥ PLF deficits in relatives of autistic individuals, suggesting that this endophenotype might be heritable. These findings could be explained by a loss of cortical excitatory/ inhibitory balance, a theory consistent with postmortem studies of autism (46) .
Finally, we assessed the correlation between the two electrophysiological measures. That both clinical and preclinical studies observed significant correlations of 15%-25% shared variance suggests that these measures are related but not redundant. It is important to note, however, that neither biomarker is specific to autism, because latency delays have been reported in dyslexia and auditory neuropathy, although similar ␥-band deficits have been demonstrated in schizophrenia (47) (48) (49) .
VPA Mouse Model of Autism
Although environmental contributions are likely multifactorial, two teratogens that have been strongly linked to autism are thalidomide and VPA (9,50 -52). The anticonvulsant VPA has been associated with adverse neurodevelopmental outcomes, including lower IQ, poor language functioning, and a 7-10ϫ relative risk for ASD (9,49 -51) . Prenatal exposure to VPA in rats is an insult-based model of autism that is increasingly being explored (see Markram et al. for review) (53), with a lasting, well-replicated phenotype that mimics the human disorder (8, 9, 54) . The VPA exposed rodents show synaptic and molecular changes consistent with autism, including hyper-excitability, serotonergic dysregulation, and reduced expression of NLGN3 (13, 15, 16, 53) . Despite this, like any rodent model of a complex human behavioral disorder, the VPA insult model has a number of shortcomings. For example, there are questions about generalizability, given that most autistic individuals were not exposed to the drug in utero. In addition, this model does not directly reflect the highly genetic etiology of autism. However, the VPA model is among the most explored insult-based models from a synaptic to behavioral level, allowing us to interpret our results in the context of this larger literature.
In the present study, VPA-exposed mice showed reduced social preference, increased repetitive behaviors, and PPI deficits. Pertinent negative findings include no group differences in locomotor activity, rotorod motor coordination, adult olfactory function, or acoustic startle, suggesting that the drug does not cause global brain dysfunction. In neonates and adults, VPA-exposed mice demonstrated deficits in communicative function, as measured by the density and latency to initiate ultrasonic vocalizations as well as their spectral content. In particular, VPA exposed males failed to emit characteristic 70 kHz "pre-mating" vocalizations when paired with a receptive female. Similar ultrasonic vocalization findings have been reported in different mouse models of ASD and other speech and language disorders (55) . As such, these mice demonstrate deficits in all three core symptom domains of autism. Replicating these findings across species bolsters the face and construct validity of this approach.
Translatable Biomarkers of Autism
The lack of a biological marker for ASD has hindered pathophysiological investigation in preclinical models. Although there has been success investigating social interactions and repetitive behaviors in mice, assessing language impairment has been especially difficult (56) . To address these limitations, this study employs a novel approach toward preclinical targets for autism. We have characterized two distinct measures of impaired auditory processing in autism, which likely reflect the abnormal neural dynamics of ASD more closely than behavioral criteria alone. With analogous methods, we demonstrate that the VPA mouse model of autism recapitulates both biomarkers. These measures predicted the severity of behavioral deficits in mice. Modeling ASD endophenotypes of impaired brain functioning in mice allows direct investigation of the neural mechanisms of these phenotypes and provides rational targets for pharmacological intervention.
Given that VPA is a Class I histone deacytlase inhibitor, it is not surprising that exposure to this drug during development causes persistent alterations in gene expression profiles (57) . Kolozsi et al. (15) demonstrated reduced messenger RNA levels of the X-linked autism risk-gene NLGN3 in adult mice exposed to VPA in utero. Our results extend previous findings to show that NLGN3 is associated with neural deficits in the VPA model. Although we did not find group differences in NLGN3 protein levels, a highly significant relationship between ␥ synchronization deficits and reduced NLGN3 expression was observed. In mice, previous studies have shown that NLGN3 downregulation significantly reduced the number of inhibitory interneurons, which are critical for ␥ synchrony (58) . In accordance, Gogolla et al. (20) demonstrated a loss of cortical fastspiking interneurons in VPA-exposed mice, a finding that is consistent across many rodent models of autism. These results indicate that the balance of excitation to inhibition is likely disrupted in the VPA model and suggest that restoring this balance might rescue phenotypic deficits.
We explored this hypothesis by assessing the effect of MPEP, a potent noncompetitive mGluR5-receptor antagonist, on PPI and electrophysiological measures. The rationale for selecting MPEP was based on the fact that mGluR5 antagonists have shown promise in clinical trials of Fragile X syndrome, which shares a significant overlap with ASD (59) . The mGluR5 antagonists have demonstrated remarkable reversal of phenotypic deficits in preclinical models of Fragile X Syndrome, including core ASD symptoms like social impairments (21, 60, 61) . Recent work has shown that MPEP is effective in reversing phenotypic deficits related to core ASD deficits in an idiopathic mouse model of autism (62) . Finally, we have recently shown that other glutamate receptor antagonists modulate ␥ oscillations in mice (63) . On the basis of this literature, we hypothesized that MPEP would be a relatively novel, promising pharmacological compound to assess in our model. Indeed, MPEP rescued PPI deficits in the VPA model, nearly identical to the effect seen in Fmr1 knockout mice (60) . It did so without affecting startle curve amplitudes, suggesting it is not overly sedating. MPEP selectively reduced N1 amplitudes, indicating a reduction in cortical excitability, but did not rescue N1 latency delays. There was a trending interactive effect of MPEP and VPA exposure on ␥ PLF, boosting ␥ synchrony in the VPA group while reducing ␥ synchrony in SAL-treated mice (Figure 4) . We hypothesize that this differential effect reflects the tightly coupled balance of excitation and inhibition in driving cortical oscillatory activity. In control mice, where this balance is optimal, we expect that reducing N-methyl-D-aspartate current with MPEP would disrupt neural synchrony. However, in VPA mice where this interplay favors excitation, we speculate that MPEP would restore appropriate balance and thus promote ␥ synchrony.
In conclusion, this study demonstrates the translational potential of STG M100 auditory evoked responses and ␥-band phaselocking in parallel human and mouse studies of autism. Although the present study focused on early ␥ frequency responses given relevant cognitive correlates, known circuit generators, and the putative ␥ abnormalities in ASD, future studies will investigate neural synchrony in lower frequency ranges and at later latencies. A limitation of this study is the different stimulus parameters between humans and mice. Human tones were chosen on the basis of the salience of this frequency range for human language (3). Because mice cannot hear these tones well, higher frequencies at corresponding places in the mouse hearing spectrum were chosen. Future work will investigate additional stimulus parameters in both clinical and preclinical settings. 
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